The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.
 
Enriqueta Felip
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche
 
Daniel Shao-Weng Tan
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis
Research Funding - Bayer; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Merck; Novartis
 
Dong-Wan Kim
No Relationships to Disclose
 
Ranee Mehra
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Sergey Orlov
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Chong-Jen Yu
No Relationships to Disclose
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Consulting or Advisory Role - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; geneDecode; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Pfizer; Roche
Consulting or Advisory Role - Lilly
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Bayer
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Santosh Sutradhar
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Dajana Cesic
Employment - Novartis
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Novartis; Pfizer; Roche/Genentech